Compare fund portfolios
See how two funds' portfolios overlap. Enter two tickers:
FPHAX vs JDOC
Shared holdings
13
FPHAX covered by JDOC
30.89%
JDOC covered by FPHAX
30.89%
Coverage = share of one portfolio's weight reproduced by the other (overlapping positions, min weight). Top 50 positions per side shown; = held by both — hover a shared position to highlight it in both columns.
FPHAX (Feb. 28, 2026)
| Security | Weight | |
|---|---|---|
| LILLY ELI and CO | 24.13% | |
| GSK plc SPONSORED ADR | 9.65% | |
| JOHNSON&JOHNSON | 7.22% | |
| UCB SA | 4.80% | |
| ROCHE HOLDINGS AG (GENUSSCHEINE) | 4.73% | |
| ASTRAZENECA PLC | 4.72% | |
| GILEAD SCIENCES INC | 4.45% | |
| MERCK & CO | 4.40% | |
| ELANCO ANIMAL HEALTH INC | 4.23% | |
| Fidelity Securities Lending Cash Central Fund | 4.08% | |
| LEGEND BIOTECH CORP SPON ADR | 3.12% | |
| JAZZ PHARMA PLC | 2.74% | |
| MODERNA INC | 2.33% | |
| ROYALTY PHARMA PLC | 2.19% | |
| VIATRIS INC | 1.63% | |
| FINANCIERE DE TU | 1.55% | |
| BIONTECH SE ADR | 0.92% | |
| MERCK Kommanditgesellschaft auf Aktien | 0.91% | |
| BIOGEN INC | 0.89% | |
| OCULAR THERAPEUTIX INC | 0.75% | |
| BEAM THERAPEUTICS INC | 0.75% | |
| XENON PHARMACEUTICALS INC | 0.73% | |
| UNIQURE N.V. | 0.70% | |
| CAPRICOR THERAPEUTICS INC | 0.69% | |
| PTC THERAPEUTICS INC | 0.67% | |
| KYMERA THERAPEUTICS INC | 0.59% | |
| PHIBRO ANIMAL HEALTH CORP CL A | 0.52% | |
| AXSOME THERAPEUTICS INC | 0.51% | |
| ANNEXON INC | 0.45% | |
| Ascendis Pharma A/S | 0.36% | |
| CORCEPT THERAPEUTICS INC | 0.36% | |
| AGOMAB THERAPEUTICS SA SER D PC PP | 0.34% | |
| INTELLIA THERAPEUTICS INC | 0.33% | |
| CRINETICS PHARMACEUTICALS INC | 0.32% | |
| Fidelity Cash Central Fund | 0.30% | |
| HARMONY BIOSCIENCES HOLDINGS INC | 0.29% | |
| ARROWHEAD PHARMACEUTICALS INC | 0.26% | |
| WAVE LIFE SCIENCES LTD | 0.26% | |
| VERA THERAPEUTICS INC | 0.26% | |
| AMYLYX PHARMACEUTICALS INC | 0.25% | |
| DISC MEDICINE INC | 0.23% | |
| DEFINIUM THERAPEUTICS INC | 0.21% | |
| IDORSIA LTD | 0.21% | |
| SUMMIT THERAPEUTICS INC | 0.18% | |
| EDGEWISE THERAPEUTICS INC | 0.16% | |
| ARRIVENT BIOPHARMA INC | 0.16% | |
| EVOZYNE INC SER B PC PP | 0.14% | |
| VIKING THERAPEUTICS INC | 0.14% | |
| PARAGON BIOSCIENCES EMALEX CAPITAL INC SER D-3 PC PP | 0.12% | |
| CASTLE CREEK BIOSCIENCES INC SER D-2 PC PP | 0.09% |
JDOC (Jan. 31, 2026)
| Security | Weight | |
|---|---|---|
| JOHNSON&JOHNSON | 7.49% | |
| LILLY ELI and CO | 7.26% | |
| ABBVIE INC | 5.46% | |
| MERCK & CO | 5.15% | |
| ASTRAZENECA PLC | 4.80% | |
| NOVO NORDISK-B | 3.68% | |
| UNITEDHEALTH GRP | 3.52% | |
| DANAHER CORP | 3.19% | |
| MEDTRONIC PLC | 3.13% | |
| ROCHE HOLDINGS AG (GENUSSCHEINE) | 2.95% | |
| BRISTOL-MYERS SQUIBB CO | 2.45% | |
| BOSTON SCIENTIFIC CORP | 2.44% | |
| CVS HEALTH CORP | 2.42% | |
| ARGENX SE | 2.37% | |
| MCKESSON CORP | 2.11% | |
| REGENERON PHARMACEUTICALS INC | 2.10% | |
| LONZA GROUP -REG | 1.97% | |
| ESSILORLUXOTTICA | 1.94% | |
| HOYA CORP | 1.93% | |
| UCB SA | 1.90% | |
| VERTEX PHARMACEUTICALS INC | 1.86% | |
| STRYKER CORP | 1.72% | |
| THERMO FISHER SCIENTIFIC INC | 1.69% | |
| CARDINAL HEALTH INC | 1.68% | |
| EDWARDS LIFESCIENCES CORP | 1.66% | |
| IQVIA HOLDINGS INC | 1.44% | |
| INTUITIVE SURGICAL INC | 1.36% | |
| TEVA PHARMACEUTICAL INDUSTRIES LTD | 1.24% | |
| Fresenius SE & Company KGaA | 1.21% | |
| Novartis AG (Registered) | 1.15% | |
| Sartorius Aktiengesellschaft | 1.05% | |
| BIOGEN INC | 0.95% | |
| AXSOME THERAPEUTICS INC | 0.91% | |
| IONIS PHARMACEUTICALS INC | 0.90% | |
| APOGEE THERAPEUTICS INC | 0.84% | |
| NEUROCRINE BIOSCIENCES INC | 0.78% | |
| Ascendis Pharma A/S | 0.77% | |
| GENMAB AS | 0.74% | |
| UNITED THERAPEUTICS CORP DEL | 0.73% | |
| IMMUNOME INC | 0.71% | |
| DISC MEDICINE INC | 0.67% | |
| DAIICHI SANKYO | 0.67% | |
| VIRIDIAN THERAPEUTICS INC | 0.66% | |
| DYNE THERAPEUTICS INC | 0.66% | |
| CG ONCOLOGY INC | 0.63% | |
| CONVATEC GROUP P | 0.59% | |
| REVOLUTION MEDICINES INC | 0.51% | |
| WATERS CORP | 0.49% | |
| CYTOKINETICS INC | 0.49% | |
| BIO-TECHNE CORP | 0.47% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.